Want to see GB:RENX full AI Analyst Report?
RENX Stock Chart & Stats
5.90 p
0.99 p(8.62%)
At close: 4:00 PM EST
5.90 p
0.99 p(8.62%)
Day’s Range― - ―
52-Week Range1.60 p - 15.50 p
Previous CloseN/A
Volume11.59K
Average Volume (3M)10.03M
Market Cap
£12.02M
Enterprise Value26.40M
Total Cash (Recent Filing)£6.20M
Total Debt (Recent Filing)£5.80M
Price to Earnings (P/E)―
Beta-0.05
Next Earnings
Nov 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding437,018,680
10 Day Avg. Volume3,807,103
30 Day Avg. Volume10,033,489
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-1.38
Price to Sales (P/S)3.23
P/FCF Ratio-0.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.24
Revenue Forecast (FY)£114.30M
Bulls Say, Bears Say
Bulls Say
Revenue Growth MomentumRevenue rising ~26% in FY2025 to roughly £3.0m shows early commercial traction for KidneyIntelX. Durable topline growth from clinician adoption and payer reimbursement can expand test volumes, enable operating leverage, and materially improve the path to scale if sustained beyond a single year.
Significant Gross Margin ImprovementA jump to ~40% gross margin in FY2025 from ~7% indicates the product has stronger unit economics once deployed. Higher gross margins are a structural enabler: as volumes scale, fixed lab and R&D costs can be absorbed, materially improving the long-term prospect for operating leverage and eventual profitability.
Differentiated AI-enabled Diagnostic OfferingKidneyIntelX's combination of biomarker assays and AI-driven clinical decision support represents a defensible, integrated diagnostic platform. This product-led differentiation can create clinical adoption barriers, support contracted deployments with health systems, and sustain recurring test volumes and payer pathways.
Bears Say
Negative Equity / Stressed Balance SheetNegative shareholders' equity persisting into FY2025 reflects cumulative losses that erode capital and reduce financial flexibility. A negative equity base typically increases reliance on external funding, limits strategic options for expansion or M&A, and heightens the risk if cash inflows underperform expectations.
Persistent Cash BurnOperating and free cash flow of roughly -£17.9m in FY2025, while improved from prior year, remain meaningfully negative. Continued cash burn necessitates recurring financing, pressures the balance sheet, risks dilution for existing holders, and constrains the company's ability to scale commercial operations without securing durable reimbursement and higher volumes.
Very Large Net LossesA net margin near -680% indicates losses vastly exceed revenue and that the current cost base is far out of line with testing income. Such deep losses mean the business needs substantial and sustained revenue growth or material cost reductions to reach break-even, creating execution and financing risk over the medium term.
Renalytix News
RENX FAQ
What was Renalytix’s price range in the past 12 months?
Renalytix lowest share price was 1.60 p and its highest was 15.50 p in the past 12 months.
What is Renalytix’s market cap?
Renalytix’s market cap is £12.02M.
When is Renalytix’s upcoming earnings report date?
Renalytix’s upcoming earnings report date is Nov 03, 2026 which is in 105 days.
How were Renalytix’s earnings last quarter?
Renalytix released its earnings results on Mar 26, 2026. The company reported -0.016 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.016 p.
Is Renalytix overvalued?
According to Wall Street analysts Renalytix’s price is currently Overvalued.
Does Renalytix pay dividends?
Renalytix does not currently pay dividends.
What is Renalytix’s EPS estimate?
Renalytix’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Renalytix have?
Renalytix has 437,018,680 shares outstanding.
What happened to Renalytix’s price movement after its last earnings report?
Renalytix reported an EPS of -0.016 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.818%.
Which hedge fund is a major shareholder of Renalytix?
Currently, no hedge funds are holding shares in GB:RENX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Renalytix
Renalytix Plc specializes in developing cutting-edge in vitro diagnostic solutions for kidney diseases, leveraging the power of artificial intelligence. Their primary offering, KidneyIntelX, is an advanced diagnostic platform. It employs a sophisticated AI-enabled algorithm that synthesizes various data streams, such as scientifically validated blood biomarkers, inherited genetic factors, and personalized patient data extracted from electronic health record systems. The output is a unique, individualized risk score for each patient. These innovative tools serve multiple critical functions: they assist in the diagnosis and prognosis of kidney ailments, optimize clinical patient management, facilitate patient stratification for pharmaceutical clinical trials, and aid in the discovery of novel drug targets. The company has secured several pivotal license agreements. A partnership with Mount Sinai Health System grants rights for the development and commercialization of AI applications in kidney disease diagnostics. Another agreement with Joslin Diabetes Center, Inc. focuses on creating and marketing biomarker-based products for the diagnosis and prediction of kidney conditions. Furthermore, Renalytix holds a license with Kantaro Biosciences LLC for laboratory assays designed to detect SARS-CoV-2 antibodies. In a collaborative effort, Renalytix has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine. This alliance aims to implement an advanced clinical care paradigm, specifically designed to enhance kidney health and mitigate the progression of kidney disease and subsequent renal failure in high-risk patient populations. Founded in 2018, the company operated under the name Renalytix AI plc until its change to Renalytix Plc in June 2021. Its corporate headquarters are situated in New York, New York.
Technical Analysis
EKF Diagnostics Holdings
―
Genedrive
―
Oxford BioDynamics
―
Proteome Sciences
―
Verici Dx Plc
―